Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
No trials found
News
FDA Issues Second Complete Response Letter for Odronextamab in Relapsed/Refractory Follicular Lymphoma
The FDA has issued a second complete response letter (CRL) for odronextamab's biologics license application, this time related to observations from an FDA site inspection at Catalent Indiana, LLC manufacturing facility.